Biosafety in the research and clinical practice dealing with emer | 6066
Virology & Mycology

Virology & Mycology
Open Access

ISSN: 2161-0517

+44 1223 790975

Biosafety in the research and clinical practice dealing with emerging viral pathogens especially in the scenario of an outbreak and respective to the point of evolution of virulence as a biosafety factor

6th Euro Virology Congress and Expo

March 10-12, 2016 Madrid, Spain

Pedro Brandao dos Santos Pedrosa

Leibniz Universit´┐Ż?┬Ąt Hannover, Germany

Scientific Tracks Abstracts: Virol-mycol

Abstract :

The previous theory of the epidemiological transition has been challenged this time by the worst EHF epidemic ever (caused by EBOV), which may pose a real threat of pandemic through the return of unresolved cases to their countries of origin. This instance exemplifies which sort of consequences the virological research community is about to deal with in the case of research of emerging/reemerging viral pathogens presenting a relevant process of evolution of virulence. The process of evolution of virulence of viral pathogens of medical importance can no longer be regarded with outdated paradigms and dogmatic or misconceived views concerning fast evolving viruses presenting an actual and significant evolution of virulence such as DENV and some coronaviruses (i.e., SARS-CoV and MERS-CoV). The lecture will present the evolution of virulence of such viral pathogens as a relevant factor concerning the biosafety of the virological research.

Biography :

Pedro Brandao dos Santos Pedrosa has obtained his BSc in Microbiology and Immunology. He is Specialist in Biosafety by FIOCRUZ (IPEC) and completed his MSc in Immunology from USP (São Paulo State University). His virology experience comprises work with Dengue virus, Hantavirus, Mayaro virus, some degree of training in BSL3 operation, training and scientific initial work in the Friedrich Loeffler Institute (FLI-INNT). He has 1 article published to his credit.